Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHY-XT is a desensitizing toothpaste developed by Group Pharmaceutical, specifically formulated for the management of dentin hypersensitivity. The product typically contains potassium nitrate and sodium monofluorophosphate as its active pharmaceutical ingredients. Potassium nitrate acts as a desensitizing agent by diffusing through the dentinal tubules to the dental pulp, where it increases the extracellular potassium ion concentration. This leads to the depolarization of the pulpal nerve membranes, effectively blocking the transmission of pain signals caused by thermal, chemical, or mechanical stimuli. Sodium monofluorophosphate serves as a source of fluoride, which promotes the remineralization of tooth enamel and provides protection against dental caries. SHY-XT is marketed as a daily-use oral care product to provide both immediate and long-term relief from tooth sensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SHY-XT.